Les Brail

516 total citations
18 papers, 427 citations indexed

About

Les Brail is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Les Brail has authored 18 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Molecular Biology and 4 papers in Immunology. Recurrent topics in Les Brail's work include Cancer Immunotherapy and Biomarkers (5 papers), Cancer Research and Treatments (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Les Brail is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Cancer Research and Treatments (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Les Brail collaborates with scholars based in United States, United Kingdom and Australia. Les Brail's co-authors include Valérie André, David S. Hong, George R. Simon, Jeffrey R. Infante, Sophie Callies, Yun Oh, Sunil Kadam, Funda Meric‐Bernstam, Aejaz Nasir and Aung Naing and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Les Brail

18 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Les Brail United States	9	323	108	75	34	33	18	427
Elizabeth Moskatel United States	3	318 1.0×	96 0.9×	67 0.9×	57 1.7×	44 1.3×	4	389
Luigi Alfano Italy	11	271 0.8×	95 0.9×	36 0.5×	56 1.6×	45 1.4×	23	396
Kerstin Maria Kampa-Schittenhelm Germany	12	283 0.9×	171 1.6×	90 1.2×	37 1.1×	55 1.7×	30	516
Gina M. Ney United States	12	273 0.8×	82 0.8×	102 1.4×	27 0.8×	82 2.5×	19	438
David Sedwick United States	6	446 1.4×	137 1.3×	48 0.6×	34 1.0×	63 1.9×	7	514
Nuzhat N. Kabir Sweden	13	253 0.8×	94 0.9×	65 0.9×	29 0.9×	63 1.9×	16	384
Luana D’Artista Italy	7	414 1.3×	228 2.1×	52 0.7×	25 0.7×	54 1.6×	9	496
Janice M. Mehnert United States	8	303 0.9×	183 1.7×	52 0.7×	36 1.1×	58 1.8×	24	409
Fanmao Zhang United States	6	270 0.8×	181 1.7×	54 0.7×	28 0.8×	77 2.3×	8	421
Holly Yin United States	7	218 0.7×	71 0.7×	44 0.6×	20 0.6×	42 1.3×	19	303

Countries citing papers authored by Les Brail

Since Specialization

Citations

This map shows the geographic impact of Les Brail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Les Brail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Les Brail more than expected).

Fields of papers citing papers by Les Brail

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Les Brail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Les Brail. The network helps show where Les Brail may publish in the future.

Co-authorship network of co-authors of Les Brail

This figure shows the co-authorship network connecting the top 25 collaborators of Les Brail. A scholar is included among the top collaborators of Les Brail based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Les Brail. Les Brail is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

1.

Wen, Patrick Y., Manmeet S. Ahluwalia, Yazmín Odia, et al.. (2024). CTNI-48. A PHASE 1 STUDY OF ERAS-801, A POTENT, SELECTIVE, AND CENTRAL NERVOUS SYSTEM (CNS)-PENETRANT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR, FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM). Neuro-Oncology. 26(Supplement_8). viii107–viii107. 1 indexed citations

2.

McKean, Meredith, Ezra Y. Rosen, Minal Barve, et al.. (2023). Abstract CT184: Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors. Cancer Research. 83(8_Supplement). CT184–CT184. 5 indexed citations

3.

Bushway, Meghan E., Ying S. Ting, Rana H. Besada, et al.. (2019). Abstract 5006: Comprehensive gene expression analysis of the tumor microenvironment in patients with advanced cancer treated with a personalized neoantigen vaccine, NEO-PV-01, in combination with anti-PD1. Cancer Research. 79(13_Supplement). 5006–5006. 1 indexed citations

4.

Bushway, Meghan E., Ying S. Ting, Rana H. Besada, et al.. (2019). Abstract 5006: Comprehensive gene expression analysis of the tumor microenvironment in patients with advanced cancer treated with a personalized neoantigen vaccine, NEO-PV-01, in combination with anti-PD1. 5006–5006. 1 indexed citations

5.

Bendell, Johanna C., Valérie André, Alan L. Ho, et al.. (2018). Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma. Clinical Cancer Research. 24(9). 2082–2091. 59 indexed citations

6.

Sullivan, Ryan J., David S. Hong, Anthony W. Tolcher, et al.. (2018). Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 3013–3013. 51 indexed citations

7.

Tolcher, Anthony W., David S. Hong, Ryan J. Sullivan, et al.. (2017). Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors. Cancer Research. 77(13_Supplement). CT089–CT089. 10 indexed citations

8.

Tolcher, Anthony W., David S. Hong, Ryan J. Sullivan, et al.. (2016). IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). TPS3111–TPS3111. 5 indexed citations

9.

Fowler, Nathan, Joseph Pearlberg, Les Brail, et al.. (2016). FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen.. Journal of Clinical Oncology. 34(15_suppl). TPS7578–TPS7578. 4 indexed citations

10.

Tolcher, Anthony W., David S. Hong, Ryan J. Sullivan, et al.. (2016). Abstract B070: IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors. Cancer Immunology Research. 4(11_Supplement). B070–B070. 2 indexed citations

11.

Gray, Jhanelle E., Jeffrey R. Infante, Les Brail, et al.. (2015). A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Investigational New Drugs. 33(6). 1187–1196. 59 indexed citations

12.

Bendell, Johanna C., Valérie André, Alan L. Ho, et al.. (2015). Abstract B32: LY2940680, a hedgehog (Hh) pathway inhibitor, demonstrates anti-tumor activity in patients with advanced basal cell carcinoma (BCC). Molecular Cancer Therapeutics. 14(12_Supplement_2). B32–B32. 2 indexed citations

13.

Hollebecque, Antoine, Nadine Houédé, Ezra E.W. Cohen, et al.. (2014). A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. European Journal of Cancer. 50(5). 876–884. 29 indexed citations

14.

Tolcher, Anthony W., Jonathan H. Goldman, Amita Patnaik, et al.. (2014). A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. European Journal of Cancer. 50(5). 867–875. 45 indexed citations

15.

Hong, David S., Razelle Kurzrock, Yun Oh, et al.. (2011). A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer. Clinical Cancer Research. 17(20). 6582–6591. 113 indexed citations

16.

Pollok, Karen E., Michael Lahn, Nathan Enas, et al.. (2009). In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography. Journal of Oncology. 2009. 1–8. 5 indexed citations

17.

Schwartz, Gary K., Aaron Weitzman, Eileen M. O’Reilly, et al.. (2005). Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB₄ Receptor Antagonist, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 23(23). 5365–5373. 26 indexed citations

18.

Bristow, Robert G., Les Brail, Anne Jang, et al.. (1996). P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. International Journal of Radiation Oncology*Biology*Physics. 34(2). 341–355. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact